Indiana Code 25-26-24-18. Program requirements; execution of contracts; data; funding
(1) Create a data base for information required to be transmitted under section 17 of this chapter in the form required under rules adopted by the board, including search capability for the following:
Terms Used In Indiana Code 25-26-24-18
- board: refers to the Indiana board of pharmacy. See Indiana Code 25-26-24-1
- committee: refers to the INSPECT oversight committee established by section 24 of this chapter. See Indiana Code 25-26-24-2
- Contract: A legal written agreement that becomes binding when signed.
- controlled substance: has the meaning set forth in IC 35-48-1-9. See Indiana Code 25-26-24-2.5
- ephedrine: includes only ephedrine that is dispensed pursuant to a prescription or drug order. See Indiana Code 25-26-24-4
- identification number: refers to the following:
Indiana Code 25-26-24-6
- in writing: include printing, lithographing, or other mode of representing words and letters. See Indiana Code 1-1-4-5
- INSPECT: means the Indiana scheduled prescription electronic collection and tracking program established by IC 25-1-13-4. See Indiana Code 25-26-24-7
- prescription: means an order for medication that is dispensed to or for a recipient. See Indiana Code 25-26-24-12
- pseudoephedrine: includes only pseudoephedrine that is dispensed pursuant to a prescription or drug order. See Indiana Code 25-26-24-13
- recipient: means an individual for whom a controlled substance is dispensed. See Indiana Code 25-26-24-14
- recipient representative: means the individual to whom a controlled substance is dispensed if the recipient is either less than eighteen (18) years of age or unavailable to receive the controlled substance. See Indiana Code 25-26-24-15
- state: means any state of the United States or the District of Columbia. See Indiana Code 25-26-24-16
- United States: includes the District of Columbia and the commonwealths, possessions, states in free association with the United States, and the territories. See Indiana Code 1-1-4-5
(B) An ephedrine, pseudoephedrine, or a controlled substance recipient’s or recipient representative‘s identification number.
(C) An ephedrine, pseudoephedrine, or a controlled substance recipient’s date of birth.
(D) The national drug code number of ephedrine, pseudoephedrine, or a controlled substance dispensed.
(E) The dates ephedrine, pseudoephedrine, or a controlled substance are dispensed.
(F) The quantities of ephedrine, pseudoephedrine, or controlled substance dispensed.
(G) The number of days of supply dispensed.
(H) A dispenser’s United States Drug Enforcement Agency registration number.
(I) A prescriber’s United States Drug Enforcement Agency registration number.
(J) Whether a prescription was transmitted to the pharmacist orally or in writing.
(K) An ephedrine, pseudoephedrine, or a controlled substance recipient’s method of payment for the ephedrine, pseudoephedrine, or controlled substance dispensed.
To the extent considered appropriate by the board, the data base must be interoperable with other similar registries operated by federal and state governments.
(2) Provide the board with continuing twenty-four (24) hour a day online access to the data base.
(3) Secure the information collected and the data base maintained against access by unauthorized persons.
(b) The board may not execute a contract with a vendor designated by the board to perform any function associated with the administration of the INSPECT program, unless the contract has been approved by the committee.
(c) The INSPECT program may gather prescription data from the Medicaid retrospective and prospective drug utilization review (DUR) program established under IC 12-15-35.
(d) The board may accept and designate grants, public and private financial assistance, and licensure fees to provide funding for the INSPECT program.
As added by P.L.51-2019, SEC.8.